AstraZeneca’s Partner, MAP Pharmaceuticals, Announces Phase III Study Of Unit Dose Budesonide In Children With Asthma Did Not Meet Primary Endpoints

Tuesday, 24 February 2009

MAP Pharmaceuticals, Inc. announced yesterday that its initial Phase III clinical trial of Unit Dose Budesonide (UDB) for the potential treatment of children with asthma did not meet its co-primary endpoints: asthma control as assessed by changes from baseline in night-time and daytime composite symptom scores, in either of the doses evaluated when compared with placebo.

AstraZeneca will work with MAP Pharmaceuticals to conduct further analyses of these data to determine appropriate next steps for the programme.

AstraZeneca and MAP Pharmaceuticals have a collaboration agreement to develop and commercialise UDB.

About AstraZeneca
AstraZeneca is a major international healthcare business engaged in the research, development, manufacturing and marketing of meaningful prescription medicines and supplier for healthcare services. AstraZeneca is one of the world's leading pharmaceutical companies with healthcare sales of US$ 31.6 billion and is a leader in gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infectious disease medicines. For more information about AstraZeneca, please visit:

About MAP Pharmaceuticals
MAP Pharmaceuticals is dedicated to developing and commercialising new therapies for children and adults suffering from chronic conditions that are not adequately treated by currently available medicines. The company has two product candidates in Phase III clinical development. Unit Dose Budesonide is being developed in collaboration with AstraZeneca for the potential treatment of asthma in children, and MAP0004 is being developed for the potential treatment of migraine. In addition, MAP Pharmaceuticals generates new pipeline opportunities by applying its proprietary drug particle and inhalation technologies to enhance the therapeutic benefits of proven drugs, while minimising risk, by capitalising on their known safety, efficacy and commercialisation history. Additional information about MAP Pharmaceuticals can be found at

Media Enquiries UK:
Chris Sampson +44 20 7304 5130 (24 hours)
Neil McCrae +44 20 7304 5045 (24 hours)
Sarah Lindgreen +44 20 7304 5033 (24 hours)

Media Enquiries US:
Emily Denney +1 302 885 3451 mob: +1 302 897 4953

Investor Enquiries UK:
Jonathan Hunt +44 207 304 5087 mob: +44 7775 704032
Karl Hard +44 207 304 5322 mob: +44 7789 654364

Investor Enquiries US:
Ed Seage +1 302 886 4065 mob: +1 302 373 1361
Jorgen Winroth +1 212 579 0506 mob: +1 917 612 4043


  • Corporate and financial